Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial
Srdan Verstovsek
Research Funding - Incyte
Jean-Jacques Kiladjian
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Martin Griesshammer
No relevant relationships to disclose
Tamás Masszi
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Simon T. S. Durrant
Research Funding - Novartis
Francesco Passamonti
Consultant or Advisory Role - Novartis (U)
Claire N. Harrison
Honoraria - Novartis
Research Funding - Novartis
Fabrizio Pane
No relevant relationships to disclose
Pierre Zachee
No relevant relationships to disclose
Ruben A. Mesa
Research Funding - Incyte
Shui He
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Mark Jones
Employment or Leadership Position - Incyte
William M. Garrett
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Jingjin Li
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Ulrich Pirron
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Tomasz Lawniczek
Employment or Leadership Position - Novartis
Alessandro M Vannucchi
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis